Table 2.
Factors Associated with Patient Outcomes at the Univariate Level
| Variables | Progression-Free Survival | Overall Survival | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Age (≥60) | 0.58 (0.32–1.07) | 0.080 | 0.77 (0.33–1.82) | 0.555 |
| Gender (female) | 1.00 (0.44–2.26) | 0.998 | 1.31 (0.38–4.48) | 0.666 |
| Presence of hepatitis (n=44) | 2.51 (1.15–5.48) | 0.021 | 1.92 (0.64–5.74) | 0.040 |
| Presence of previous treatments (n=45) | 1.67 (0.79–3.53) | 0.183 | 2.46 (0.16–4.72) | 0.155 |
| Tumor size (≥1.5cm) | 2.44 (1.12–5.33) | 0.025 | 1.13 (0.91–4.80) | 0.042 |
| Pre-treatment red blood cell (≥4.5x1012/L) | 0.27 (0.12–0.60) | 0.001 | 0.52 (0.19–1.39) | 0.046 |
| Pre-treatment AFP (≥20.0 ng/mL) | 1.01 (0.48–1.68) | 0.049 | 1.13 (0.54–2.81) | 0.031 |
| Gross tumor volume (≥29.3cm3) | 1.49 (0.78–2.83) | 0.226 | 1.99 (1.23–2.71) | 0.070 |
| Biologically effective dose (≥96.0 Gy) | 0.63 (0.28–1.44) | 0.269 | 0.92 (0.31–2.73) | 0.870 |
| Pre-treatment NLR (≥3.5) | 1.22 (0.51–1.93) | 0.450 | 0.95 (0.38–3.14) | 0.110 |
| Pre-treatment PLR (≥78.8) | 1.73 (0.84–3.57) | 0.136 | 1.17 (0.47–2.93) | 0.733 |
| Post-treatment NLR (≥6.5) | 2.36 (1.20–4.65) | 0.013 | 3.70 (1.53–8.93) | 0.002 |
| Post-treatment PLR (≥263.0) | 2.25 (1.12–4.53) | 0.024 | 3.21 (1.27–8.11) | 0.009 |
| Change in NLR (≥2.7-fold) | 2.74 (1.28–5.87) | 0.009 | 2.83 (1.12–7.17) | 0.028 |
| Change in PLR (≥2.5-fold) | 1.63 (0.73–3.63) | 0.236 | 2.86 (1.12–7.28) | 0.028 |
Abbreviations: AFP, alpha-fetoprotein; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte; HR, hazard ratio; CI, confidence interval.